333437-34-6 Usage
Uses
Used in Pharmaceutical Research:
2-(piperidin-1-ylcarbonyl)cyclohexanecarboxylic acid is used as a key intermediate in the synthesis of pharmaceutical agents for its ability to modify the properties of the cyclohexane ring, contributing to the development of new drugs with enhanced therapeutic effects.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(piperidin-1-ylcarbonyl)cyclohexanecarboxylic acid is utilized as a versatile molecule for the exploration of its potential biological activity and the creation of novel bioactive compounds with improved pharmacological profiles.
Used in Drug Development:
2-(piperidin-1-ylcarbonyl)cyclohexanecarboxylic acid is employed in drug development as a promising candidate for therapeutic applications, potentially leading to the discovery of new pharmaceutical agents with innovative mechanisms of action and improved safety and efficacy profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 333437-34-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,3,4,3 and 7 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 333437-34:
(8*3)+(7*3)+(6*3)+(5*4)+(4*3)+(3*7)+(2*3)+(1*4)=126
126 % 10 = 6
So 333437-34-6 is a valid CAS Registry Number.
InChI:InChI=1/C13H21NO3/c15-12(14-8-4-1-5-9-14)10-6-2-3-7-11(10)13(16)17/h10-11H,1-9H2,(H,16,17)
333437-34-6Relevant articles and documents
(1 R,2 R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3- b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A potent and highly selective cathepsin k inhibitor for the treatment of osteoarthritis
Dossetter, Alexander G.,Beeley, Howard,Bowyer, Jonathan,Cook, Calum R.,Crawford, James J.,Finlayson, Jonathan E.,Heron, Nicola M.,Heyes, Christine,Highton, Adrian J.,Hudson, Julian A.,Jestel, Anja,Kenny, Peter W.,Krapp, Stephan,Martin, Scott,MacFaul, Philip A.,McGuire, Thomas M.,Gutierrez, Pablo Morentin,Morley, Andrew D.,Morris, Jeffrey J.,Page, Ken M.,Ribeiro, Lyn Rosenbrier,Sawney, Helen,Steinbacher, Stefan,Smith, Caroline,Vickers, Madeleine
, p. 6363 - 6374 (2012/09/25)
Directed screening of nitrile compounds revealed 3 as a highly potent cathepsin K inhibitor but with cathepsin S activity and very poor stability to microsomes. Synthesis of compounds with reduced molecular complexity, such as 7, revealed key SAR and demonstrated that baseline physical properties and in vitro stability were in fact excellent for this series. The tricycle carboline P3 unit was discovered by hypothesis-based design using existing structural information. Optimization using small substituents, knowledge from matched molecular pairs, and control of lipophilicity yielded compounds very close to the desired profile, of which 34 (AZD4996) was selected on the basis of pharmacokinetic profile.
